Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avastin Growth Not Limited To Breast Cancer In 2008, Genentech Says

Executive Summary

Genentech anticipates continued sales growth for its blockbuster oncologic Avastin regardless of whether it is approved for first-line treatment of metastatic breast cancer

You may also be interested in...



From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy

From Playing It Safe To All-In: Genentech Takes Risks With Oncology Pipeline

Compared to its old oncology R&D lineup, Genentech's current cancer pipeline makes it clear that the company is embracing a new, riskier development strategy

Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS

The failure of Genentech's Rituxan in a Phase II/III trial in primary progressive multiple sclerosis adds weight to the idea that B cells do not play a role in the disease and may cast doubt on rituximab's potential in lupus

Related Content

UsernamePublicRestriction

Register

PS049196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel